Case Reports

Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy


 

Skin may show the first clinical evidence of systemic disease and can be the first clue to malignancy in 1% of cases.1 Dermatomyositis is an immunologically mediated inflammatory myopathy characterized by proximal muscle weakness, muscle inflammation, and characteristic skin findings.2 It has an incidence of 1 in 100,000 patients.3 In 15%- 30% cases of dermatomyositis, an underlying malignancy is the cause of paraneoplastic syndrome.4,5 Ovarian and breast cancer in women and lung cancer in men are the most common malignancies associated with dermatomyositis.6
Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

The Perfect Storm: Delivery system reform and precision medicine for all
MDedge Hematology and Oncology
Tamoxifen benefits premenopausal breast cancer patients
MDedge Hematology and Oncology
‘Extreme’ monitoring fails to boost survival in breast cancer patients
MDedge Hematology and Oncology
Full course of AI keeps disease at bay longer
MDedge Hematology and Oncology
High ER expression + high RS spells high risk for late distant recurrence
MDedge Hematology and Oncology
ASCO issues guidelines for HR+ metastatic breast cancer
MDedge Hematology and Oncology
Exercise linked to fewer cardiovascular events in nonmetastatic breast cancer patients
MDedge Hematology and Oncology
Mining for information, participation in clinical trials
MDedge Hematology and Oncology
Effects of exercise interventions during different treatments in breast cancer
MDedge Hematology and Oncology
Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus
MDedge Hematology and Oncology